Capecitabine in association with epirubicin and docetaxel as a first line treatment in advanced breast cancer. A multicenter phase II study.

被引：0
|
作者：
Rosso, R
Del Mastro, L
Durando, A
Garrone, O
Cherubini, R
Scotto, T
Genta, F
Occelli, M
Bellino, R
Bighin, C
Catzeddu, T
Stevani, I
Baldini, A
Lambiase, A
Venturini, M
机构：
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Turin, Osped S Anna, Dipartimento Ginecol, Turin, Italy
[3] Osped S Croce & Carle, Cuneo, Italy
[4] Policlin Monteluce, Perugia, Italy
[5] Axienda Osped USL 1, Sassari, Italy
[6] Policlin San Matteo, I-27100 Pavia, Italy
[7] Univ Pavia, I-27100 Pavia, Italy
[8] Roche SPA, Milan, Italy
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页码：270 / 270
页数：1
相关论文
共 50 条
  • [1] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [2] Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
    Mavroudis, D
    Alexopoulos, A
    Ziras, N
    Malamos, N
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Tsavaris, N
    Potamianou, A
    Rigatos, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 (10) : 1249 - 1254
  • [3] Phase II multicenter sequential study of docetaxel (T) and epirubicin (E) followed by docetaxel (T) and capecitabine (X) as first-line treatment of advanced or metastatic breast cancer (MBC).
    Ramos, M
    Casal, J
    Galán, A
    Almanza, C
    León, L
    Amenedo, M
    Gonzalez, A
    Huidobro, G
    Giner, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 54S - 54S
  • [4] Multicentric phase II study of epirubicin and docetaxel as first line treatment for patients with advanced gastric cancer: A GERCOR study.
    Nguyen, S
    Flesch, M
    Bennamoun, M
    Salle, F
    Angellier, E
    Carola, E
    Berdah, JF
    Cattan, S
    Magherini, E
    Louvet, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 328S - 328S
  • [5] A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
    Mavroudis, D
    Boukovinas, I
    Ardavanis, A
    Syrigos, K
    Kouroussis, CH
    Kakolyris, S
    Malamos, N
    Athanasiadis, A
    Varthalitis, I
    Potamianou, A
    Georgoulias, V
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [6] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    S. H. Waters
    A. Gillibrand
    H. Berry
    S. Kumar
    G. Velikova
    D. J. Dodwell
    Timothy J. Perren
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 407 - 412
  • [7] Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer
    Waters, S. H.
    Gillibrand, A.
    Berry, H.
    Kumar, S.
    Velikova, G.
    Dodwell, D. J.
    Perren, Timothy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 407 - 412
  • [8] A Phase II study of gefitinib combined with docetaxel as first-line treatment in patients with advanced breast cancer.
    Ciardiello, F
    Troiani, T
    Caputo, F
    De Laurentiis, M
    Palmieri, G
    Marinelli, A
    Colantuoni, G
    Diadema, MR
    De Placido, S
    Bianco, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
  • [9] First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study
    Pectasides, D
    Dimopoulos, MA
    Aravantinos, G
    Kalophonos, HP
    Papacostas, P
    Briasoulis, E
    Cogas, E
    Papadimitriou, C
    Skarlos, D
    Kosmidis, P
    Fountzilas, G
    ANTICANCER RESEARCH, 2001, 21 (05) : 3575 - 3580
  • [10] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
12345